Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356–61.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602.
   Google Scholar
• Sorsa T, Konttinen YT, Lindy 0, Ftitchlin C, Saari H, Suomalainen K, et al. Collagenase in synovitis of rheumatoid arthritis. Semin Arthritis Rheum 1992;22:44–53.
   PubMed Web of Science ®Google Scholar
• Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781–90.
   PubMed Web of Science ®Google Scholar
• Muller-Ladner U, Kriegsmann J, Gay RE, Gay S. Oncogenes in rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:675–90.
   PubMed Web of Science ®Google Scholar
• Bromley M, Woolley DE. Chondroclasts and osteoclasts at sub-chondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984;27:968–75.
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone re-sorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943–51.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nishikaku F, Nakatuka M, Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J Ftheumatol 1998;25:1154–60.
   Google Scholar
• Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, et al. A new mechanism of bone destruction in rheu-matoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997;240:279–86.
   PubMed Web of Science ®Google Scholar
• Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukocyte Biol 1999;65:715–24.
   Google Scholar
• Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345–57.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identi-cal to TFtANCE/FtANKL. Proc Natl Acad Sci USA 1998;95:3597–602.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Nakamura I, Inoue J, Oda H, Nakamura K. Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab 2003;21:123–33.
   PubMed Web of Science ®Google Scholar
• Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997;234:137–42.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteodast differentiation and activation. Nature 2003;423:337–42.
   Google Scholar
• Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, et al. Tumor necrosis factor receptor-associated factor (TFtAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 2000;254:14–24.
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset os-teoporosis and arterial calcification. Genes Dev 1998;12:1260–8.
   PubMed Web of Science ®Google Scholar
• Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibi-tory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610–5.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Ar-thritis Rheum 2000;43:259–69.
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250–8.
   PubMed Web of Science ®Google Scholar
• Romas E, Bakharevski 0, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000;43:821–6.
   Google Scholar
• Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/ osteoprotegerin balance. J Immunol 2003;170:2655–62.
   Google Scholar
• Kong YY, Feige U, Sarosi I, BoIon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adju-vant arthritis through osteoprotegerin ligand. Nature 1999;402: 304–9.
   PubMed Web of Science ®Google Scholar
• Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, 40. Lang S, et al. Tumor necrosis factor alpha-mediated joint destruc-tion is inhibited by targeting osteoclasts with osteoprotegerin. Ar- thritis Rheum 2002;46:785-92.41.
   Google Scholar
• Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TFtANCE/FtANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.42.
   Google Scholar
• Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with 43. osteoprotegerin or parathyroid hormone in tumor necrosis factor- mediated arthritis. Am J Pathol 2004;164:543-55.44.
   Google Scholar
• ZwerinaJ, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and FtANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone 45. erosion, and cartilage destruction. Arthritis Rheum 2004;50: 277–90.
   Google Scholar
• Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, et al. Clinical trials in the gene therapy of arthritis. Clin 46. Orthop 2000;5300–7.
   Google Scholar
• Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther 2004;11:379–89.
   Google Scholar
• Tanaka S, Takahashi T, Takayanagi H, Miyazaki T, Oda H, 47. Nakamura K, et al. Modulation of osteoclast function by adenovi-rus vector-induced epidermal growth factor receptor. J Bone Miner Res 1998;13:1714-20.48.
   Google Scholar
• Takayanagi H, Juji T, Miyazaki T, Ezuka H, Takahashi T, Isshiki M, et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin 49. Invest 1999;104:137–46.
   PubMed Web of Science ®Google Scholar
• Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997;13:513-609.50.
   Google Scholar
• Soriano P, Montgomery C, Geske R, Bradley A. Targeted disrup-tion of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64:693–702.
   PubMed Web of Science ®Google Scholar
• Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR, Soriano P. 51. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 1993;90: 4485–9.
   Google Scholar
• Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Require-ment of pp60c-src expression for osteoclasts to form ruffled bor- 52. ders and resorb bone in mice. J Clin Invest 1992;90: 1622–7.
   Google Scholar
• Home WC, Neff L, Chatterjee D, Lomri A, Levy JB, Baron R. Osteodasts express high levels of pp60c-src in association with intracellular membranes. J Cell Biol 1992;119:1003–13.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Takahashi N, Udagawa N, Sasaki T, Fukui Y, Kurokawa T, et al. Osteoclasts express high levels of p60c-src, preferentially 53. on ruffled border membranes. FEBS Lett 1992;313:85–9.
   PubMed Web of Science ®Google Scholar
• Brown MT, Cooper JA. Regulation, substrates and functions of 54. src. Biochim Biophys Acta 1996;1287:121–49.
   PubMed Web of Science ®Google Scholar
• Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. CSK: a protein-tyrosine kinase involved in regulation of src family kinases. J Biol Chem 1991;266:24249–52.
   Google Scholar
• Miyazaki T, Takayanagi H, Isshiki M, Takahashi T, Okada M, Fukui Y, et al. In vitro and in vivo suppression of osteoclast func-tion by adenovirus vector-induced csk gene. J Bone Miner Res 2000;15:41–51.
   PubMed Web of Science ®Google Scholar
• Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991;349:117–27.
   Google Scholar
• Gay S, Gay RE. Cellular basis and oncogene expression of rheu-matoid joint destruction. Ftheumatol Int 1989;9:105–13.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Fukuda A, Seto H, Miyazaki T, Kadono Y, Sawada Y, et al. Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis Rheum 2003;48:2682–92.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, et al. Reciprocal role of ERK and NF-kappaB path-ways in survival and activation of osteoclasts. J Cell Biol 2000;148:333–42.
   PubMed Web of Science ®Google Scholar
• Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, et al. Direct gene delivery to synovium. An evalua-tion of potential vectors in vitro and in vivo. Arthritis Rheum 1996;39:820–8.
   Google Scholar
• Hunziker EB, Rosenberg LC. Repair of partial-thickness defects in articular cartilage: cell recruitment from the synovial membrane. J Bone Joint Surg Am 1996;78:721–33.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Solchaga LA, Caplan AI, Yoo JU, Goldberg VM, Johnstone B. Chondroprogenitor cells of synovial tissue. Arthritis Rheum 1999;42:2631–7.
   PubMed Web of Science ®Google Scholar
• De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001;44:1928–42.
   Google Scholar
• Seto H, Kamekura S, Miura T, Yamamoto A, Chikuda H, Ogata T, et al. Distinct roles of Smad pathways and p38 pathways in carti-lage-specific gene expression in synovial fibroblasts. J Clin Invest 2004;113:718–26.
   PubMed Web of Science ®Google Scholar
• Zhen X, Wei L, Wu Q, Zhang Y, Chen Q. Mitogen-activated protein kinase p38 mediates regulation of chondrocyte differ-entiation by parathyroid hormone. J Biol Chem 2001;276: 4879–85.
   Google Scholar
• Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regu-lated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501–12.
   PubMed Web of Science ®Google Scholar
• Mountain A. Gene therapy: the first decade. Trends Biotechnol 2000;18:119–28.
   PubMed Web of Science ®Google Scholar
• Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999;10:440–7.
   PubMed Web of Science ®Google Scholar